Acacia Pharma Group (ACPGF) Stock Price, News & Analysis

Company Overview

Acacia Pharma Group plc (OTCMKTS:ACPgf) is a commercial-stage specialty pharmaceutical company focused on developing and marketing treatments for patients in acute care settings. The company’s primary therapeutic area is perioperative and procedural supportive care, where it seeks to address unmet needs in anesthesia, sedation and postoperative nausea and vomiting. Acacia Pharma operates through a lean commercial organization in the United States and maintains its corporate headquarters in London, England.

Acacia Pharma’s lead product, BARHEMSYS, is a fixed-dose combination antiemetic approved by the U.S. Food and Drug Administration for the prevention and treatment of postoperative nausea and vomiting (PONV). The company also commercializes BYFAVO (remimazolam), an ultra-short-acting benzodiazepine indicated for procedural sedation in adults. Both products were launched in the United States in 2019 and 2020, respectively, leveraging Acacia Pharma’s specialized sales and marketing infrastructure to engage hospital systems and anesthesia providers.

Founded in 2014, Acacia Pharma has built a development pipeline that includes additional acute care candidates and formulation improvements. The company’s R&D efforts focus on leveraging existing clinical data and regulatory pathways to bring novel or enhanced therapies to market more efficiently. Acacia Pharma collaborates with contract research organizations and manufacturing partners to streamline development and scale production for its commercial products.

Acacia Pharma serves the United States as its core market, with ongoing efforts to secure partnerships and regulatory filings in Europe and other regions. The company is led by Chief Executive Officer Andrew J. Bailey, who joined in 2018 and brings extensive experience in commercial strategy and pharmaceutical licensing. Under his leadership, Acacia Pharma continues to expand its acute care portfolio and explore strategic alliances to broaden its geographic reach and therapeutic scope.

Key Stats

• Today's Range: $0.99 to $0.99
• 50-Day Range: $0.99 to $0.99
• 52-Week Range: $0.76 to $4.00
• Volume: N/A
• Average Volume: 4,104 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACPGF Stock Analysis - Frequently Asked Questions

How have ACPGF shares performed this year?

Acacia Pharma Group's stock was trading at $0.99 at the beginning of the year. Since then, ACPGF shares have increased by 0.0% and is now trading at $0.99.

How do I buy shares of Acacia Pharma Group?

Shares of ACPGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceuticals - Major
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ACPGF
• CIK: N/A
• Web: www.acaciapharma.com
• Phone: 44 1223 919760
• Fax: N/A
• Employees: 72
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A